Last reviewed · How we verify
NB-002
At a glance
| Generic name | NB-002 |
|---|---|
| Sponsor | NanoBio Corporation |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Dose Escalation and Expansion Study of NB002 in Participants With Advanced or Metastatic Solid Tumors (PHASE1)
- Treatment of Mild to Moderate Distal Subungual Onychomycosis of the Toenail (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NB-002 CI brief — competitive landscape report
- NB-002 updates RSS · CI watch RSS
- NanoBio Corporation portfolio CI